Thomas Kelan L H, Ellingrod Vicki L
Clinical Pharmacogenomics Laboratory, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109-1065, USA.
Pharmacotherapy. 2009 Jul;29(7):822-31. doi: 10.1592/phco.29.7.822.
The selective serotonin reuptake inhibitors (SSRIs) have become one of the most widely prescribed classes of drugs. They are relatively safe for the pharmacologic treatment of various psychiatric disorders; however, certain patients cannot tolerate some adverse drug reactions associated with this drug class. In addition, clinicians currently have no way to predict who will respond appropriately to a given SSRI, and the paradigm of trial and error is especially distressing for patients with mental illness. Pharmacogenetic association studies may provide insight into which genetic polymorphisms might be clinically relevant for individualizing pharmacotherapeutic regimens. Thus, we reviewed and summarized the literature regarding the pharmacogenomics of SSRI-associated adverse drug reactions. This growing body of knowledge may inform subsequent design of pharmacogenetic studies with respect to adverse drug reactions. As we appreciate the many pharmacologic mechanisms related to adverse drug reactions and gain polymorphic functional data, we will have opportunities to refine hypotheses for future pharmacogenetic association analyses.
选择性5-羟色胺再摄取抑制剂（SSRIs）已成为处方量最大的药物类别之一。它们对各种精神障碍的药物治疗相对安全；然而，某些患者无法耐受与该类药物相关的一些药物不良反应。此外，临床医生目前无法预测谁会对某种特定的SSRI产生适当反应，而反复试验的模式对患有精神疾病的患者来说尤其痛苦。药物遗传学关联研究可能有助于了解哪些基因多态性在个体化药物治疗方案中可能具有临床相关性。因此，我们回顾并总结了有关SSRI相关药物不良反应的药物基因组学的文献。这一不断增长的知识体系可能为后续关于药物不良反应的药物遗传学研究设计提供参考。随着我们深入了解与药物不良反应相关的多种药理机制并获得多态性功能数据，我们将有机会完善未来药物遗传学关联分析的假设。
